Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Net Margin (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Net Margin for 16 consecutive years, with 342.49% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 23560.0% to 342.49% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.27% through Dec 2025, down 1834.0% year-over-year, with the annual reading at 46.3% for FY2025, 1837.0% down from the prior year.
  • Net Margin hit 342.49% in Q4 2025 for Ironwood Pharmaceuticals, down from 32.87% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 376.11% in Q2 2021 to a low of 1014.58% in Q2 2023.
  • Historically, Net Margin has averaged 35.03% across 5 years, with a median of 30.29% in 2025.
  • Biggest five-year swings in Net Margin: plummeted -105272bps in 2023 and later surged 101367bps in 2024.
  • Year by year, Net Margin stood at 35.31% in 2021, then skyrocketed by 203bps to 106.95% in 2022, then plummeted by -101bps to 1.48% in 2023, then plummeted by -7121bps to 106.89% in 2024, then plummeted by -220bps to 342.49% in 2025.
  • Business Quant data shows Net Margin for IRWD at 342.49% in Q4 2025, 32.87% in Q3 2025, and 27.71% in Q2 2025.